within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB09_Idursulfase;

model Idursulfase
  extends Pharmacolibrary.Drugs.ATC.A.A16AB09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Idursulfase is a recombinant enzyme replacement therapy used for the treatment of Hunter syndrome (mucopolysaccharidosis II), a rare lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. The drug is approved for use in patients with this genetic condition and is administered via intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on data from male pediatric and adult patients with Hunter syndrome (MPS II) receiving 0.5 mg/kg intravenous infusions of idursulfase once weekly.</p><h4>References</h4><ol><li><p>Xie, H, et al., &amp; McCauley, TG (2015). Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. <i>PloS one</i> 10(4) e0122453–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0122453&quot;>10.1371/journal.pone.0122453</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25836678/&quot;>https://pubmed.ncbi.nlm.nih.gov/25836678</a></p></li><li><p>Whiteman, DA, &amp; Kimura, A (2017). Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. <i>Drug design, development and therapy</i> 11 2467–2480. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S139601&quot;>10.2147/DDDT.S139601</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28860717/&quot;>https://pubmed.ncbi.nlm.nih.gov/28860717</a></p></li><li><p>Muenzer, J, et al., &amp; Alexanderian, D (2022). Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 24(7) 1437–1448. DOI:<a href=&quot;https://doi.org/10.1016/j.gim.2022.04.002&quot;>10.1016/j.gim.2022.04.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35588317/&quot;>https://pubmed.ncbi.nlm.nih.gov/35588317</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Idursulfase;
